For the definitive diagnosis of PCa, clinical stages and treatment selection are based on the prostate-specific antigen (PSA) level, tumor TNM (tumor, nodes, and metastases) stage and Gleason score of the prostate tissue shown through histopathological examination and transrectal ultrasound guided biopsy [3, 4]. Here, KLK3 is linked to posterior cortical atrophy.